Wikisage, the free encyclopedia of the second generation, is digital heritage
Aspirin: Difference between revisions
Jump to navigation
Jump to search
m (hide) |
mNo edit summary |
||
| Line 4: | Line 4: | ||
<ref>[https://www.mdpi.com/2077-0383/8/1/104/htm Clopidogrel versus Ticagrelor for Secondary Prevention after Coronary Artery Bypass Grafting]</ref> | <ref>[https://www.mdpi.com/2077-0383/8/1/104/htm Clopidogrel versus Ticagrelor for Secondary Prevention after Coronary Artery Bypass Grafting]</ref> | ||
[[File:Kawasaki_tongue_1.jpg|thumb]] | [[File:Kawasaki_tongue_1.jpg|thumb]] | ||
==Kawasaki== | ==[[Kawasaki disease|Kawasaki]]== | ||
Protocols recommend AAs and intravenous immunoglubin; however many cases have be shown to be refractory to this treatment | Protocols recommend AAs and intravenous immunoglubin; however many cases have be shown to be refractory to this treatment | ||
Revision as of 12:51, 24 January 2019
Aspirin is an NSAID [1] A recommendation of AAs-clopidogrel to maintain the patency of the stent following coronary intervention. Clopidogrel is a P2Y12 inhibiting platelet agent; the combination AAs Ticagrelor wasn´t better than clopidogrel+aspirin [2]
Kawasaki
Protocols recommend AAs and intravenous immunoglubin; however many cases have be shown to be refractory to this treatment [3]
Hutchinson Gliford Progeria
Low dosis Aspirin 2-3 mg/Kg body weight is recommended for prevention of cardiovascular and stroke complications [4]
ATC
Salicylic acid and derivates
- Acetylsalicylic acid (INN)
